Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma
Abdulrahman Nasiri/LinkedIn, Mostafa Faisal Mohammed Saleh/LinkedIn
Mar 2, 2026, 15:42

Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma

Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared Mostafa Faisal Mohammed Saleh’s post on LinkedIn, adding:

”Honored to contribute to this review published in Current Oncology MDPI, evaluating a decade of evidence on second or salvage autologous stem cell transplantation in relapsed multiple myeloma.

This work reinforces that ASCT2 remains a clinically meaningful, risk-adapted option for selected patients, particularly those with prolonged first remission and chemosensitive relapse, even in the era of CAR-T and bispecific antibodies.

Grateful to collaborate with distinguished colleagues  Marwa Nassar, Nourah Alzaidy, Amr Hanbali, Mahmoud Aljurf, and Mostafa Faisal Mohammed Saleh.

It was a privilege to work together on this important analysis.”

Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

”Our recent review just out in Current Oncology: ASCT2 in relapsed MM (2016 – 2026) across14 key studies.
Feasible and safe: NRM 1–4% (day 100–1y) across large registries (n=305–975).
Median PFS 9.8–30.2 mo; OS ~30 to >80 mo depending on risk.
Interval ≥24 mo from ASCT1 = strongest predictor → PFS 17–45 mo; OS >60–80 mo in favorable subsets.
Maintenance matters: lenalidomide PFS 41 vs 21.6 mo; carfilzomib-dex TTP 25.1 vs 16.7 mo.
Phase III GMMG ReLApsE: no PFS/OS superiority (20.5 vs 19.3 mo; OS 67.1 vs 62.7) → selection is key.
In the CAR-T/bispecific era, ASCT2 = risk-adapted consolidation or bridge — not routine salvage.”

Title: Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review

Authors: Marwa Nassar, Nourah Alzaidy, Abdulrahman Nasiri, Amr Hanbali, Mahmoud A. Aljurf, Mostafa F. Mohammed Saleh

Read the Full Article on Current Oncology․

Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma

Stay updated on all scientific advances with Hemostasis Today.

Abdulrahman Nasiri Amr Hanbali ASCT2 CAR-T Current Oncology Health Hematology Hemostasis News Hemostasis Today Mahmoud A. Aljurf Marwa Nassar Medicine Mostafa F. Mohammed Saleh multiple myeloma Nourah Alzaidy
NewsFeed